ZA200304415B - Immunotherapeutic combinations for the treatment of tumors. - Google Patents

Immunotherapeutic combinations for the treatment of tumors. Download PDF

Info

Publication number
ZA200304415B
ZA200304415B ZA200304415A ZA200304415A ZA200304415B ZA 200304415 B ZA200304415 B ZA 200304415B ZA 200304415 A ZA200304415 A ZA 200304415A ZA 200304415 A ZA200304415 A ZA 200304415A ZA 200304415 B ZA200304415 B ZA 200304415B
Authority
ZA
South Africa
Prior art keywords
receptor
tyrosine kinase
kinase activity
antibody against
egf
Prior art date
Application number
ZA200304415A
Other languages
English (en)
Inventor
Rolando Perez Rodriquez
Tania Crombet Ramos
Gisela Maria Gonzale Marinello
Irene Beausoleil Delgado
Original Assignee
Ct De Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Immunologia Molecular filed Critical Ct De Immunologia Molecular
Publication of ZA200304415B publication Critical patent/ZA200304415B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001104Epidermal growth factor receptors [EGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00113Growth factors
    • A61K39/001131Epidermal growth factor [EGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00113Growth factors
    • A61K39/001134Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200304415A 2000-12-08 2003-06-05 Immunotherapeutic combinations for the treatment of tumors. ZA200304415B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20000287A CU22979A1 (es) 2000-12-08 2000-12-08 Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina

Publications (1)

Publication Number Publication Date
ZA200304415B true ZA200304415B (en) 2004-07-07

Family

ID=40261022

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200304415A ZA200304415B (en) 2000-12-08 2003-06-05 Immunotherapeutic combinations for the treatment of tumors.

Country Status (26)

Country Link
US (2) US20020160014A1 (es)
EP (2) EP2005996A3 (es)
JP (2) JP2005519023A (es)
KR (1) KR20030064416A (es)
CN (1) CN1326566C (es)
AR (1) AR031641A1 (es)
AT (1) ATE403438T1 (es)
AU (2) AU2152102A (es)
BR (1) BR0116010A (es)
CA (1) CA2431199C (es)
CU (1) CU22979A1 (es)
CY (1) CY1108474T1 (es)
DE (1) DE60135248D1 (es)
DK (1) DK1350521T3 (es)
EA (1) EA007381B1 (es)
ES (1) ES2311036T3 (es)
HK (1) HK1073244A1 (es)
MX (1) MXPA03005030A (es)
MY (1) MY138833A (es)
NZ (1) NZ526284A (es)
PE (1) PE20020695A1 (es)
PT (1) PT1350521E (es)
SI (1) SI1350521T1 (es)
UY (1) UY27058A1 (es)
WO (1) WO2002045747A1 (es)
ZA (1) ZA200304415B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
MX2009003738A (es) * 2006-10-12 2009-07-17 Forerunner Pharma Res Co Ltd Diagnóstico y tratamiento de cáncer usando anticuerpo anti-ereg.
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
KR101290503B1 (ko) 2008-01-17 2013-07-26 아이알엠 엘엘씨 개선된 항-trkb 항체
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
EP3583113A4 (en) * 2017-02-17 2020-08-26 George Todaro USE OF TGF-ALPHA FOR TREATMENT OF DISEASES AND DISORDERS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPH01221326A (ja) * 1988-02-29 1989-09-04 Toyo Jozo Co Ltd 悪性腫瘍細胞障害剤
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
EP0586002B1 (en) * 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
CA2137639C (en) * 1993-12-09 1999-01-26 Agustin B. L. Davila Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DE69827621T9 (de) * 1997-05-12 2007-06-06 Aphton Corp., Woodland Immunogene zusammensetzungen gegen den cck-b-gastrin-rezeptor und verfahren zur behandlung von tumoren
US20030219380A1 (en) * 1997-11-07 2003-11-27 Annie Fong Method of determining an efficacious dose of a drug
EP1075184A4 (en) * 1998-05-08 2002-01-30 Sloan Kettering Inst Cancer ACTIVE VACCINATION COMPOSITIONS AND METHODS
KR20010071271A (ko) * 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
AU2001259452A1 (en) * 2000-05-05 2001-11-20 Aphton Corporation Chimeric peptide immunogens their preparation and use
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas

Also Published As

Publication number Publication date
CU22979A1 (es) 2004-09-09
ATE403438T1 (de) 2008-08-15
MY138833A (en) 2009-07-31
DE60135248D1 (de) 2008-09-18
AU2152102A (en) 2002-06-18
NZ526284A (en) 2004-11-26
CN1326566C (zh) 2007-07-18
ES2311036T3 (es) 2009-02-01
EP2005996A3 (en) 2012-01-25
US20020160014A1 (en) 2002-10-31
CA2431199C (en) 2011-10-04
JP2005519023A (ja) 2005-06-30
KR20030064416A (ko) 2003-07-31
UY27058A1 (es) 2002-03-22
SI1350521T1 (sl) 2008-12-31
JP2010150286A (ja) 2010-07-08
US20060188497A1 (en) 2006-08-24
EA007381B1 (ru) 2006-10-27
HK1073244A1 (en) 2005-09-30
CY1108474T1 (el) 2014-04-09
DK1350521T3 (da) 2008-11-10
AR031641A1 (es) 2003-09-24
EP1350521B1 (en) 2008-08-06
EA200300646A1 (ru) 2003-10-30
CA2431199A1 (en) 2002-06-13
PE20020695A1 (es) 2002-09-23
MXPA03005030A (es) 2004-09-10
PT1350521E (pt) 2008-11-14
CN1592636A (zh) 2005-03-09
WO2002045747A1 (es) 2002-06-13
AU2002221521B2 (en) 2007-01-04
EP2005996A2 (en) 2008-12-24
US7744871B2 (en) 2010-06-29
BR0116010A (pt) 2004-01-06
EP1350521A1 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
US7744871B2 (en) Immunotherapeutic combination for the treatment of tumors that over-express receptors with tyrosine kinase activity
RU2473560C2 (ru) Совместная химиотерапия и иммунотерапия
EP1844788B1 (en) HER-2/neu multi-peptide vaccine
TW201622743A (zh) 免疫原醣肽、包含該醣肽之組合物及其用途
JP2005508838A (ja) 膵癌の組合せ治療
Saavedra et al. CIMAvax-EGF: Toward long-term survival of advanced NSCLC
US20190275132A1 (en) Divalent vaccine compositions and the use thereof for treating tumors
Lorente et al. Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF
KR20030061424A (ko) 전환 성장 인자 알파를 함유하는 백신 조성물
Ede et al. Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers
Alpízar et al. HER1-ECD vaccination dispenses with emulsification to elicit HER1-specific anti-proliferative effects
MX2014007919A (es) Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliosido n-glicolil gm3 (neugcgm3).
NZ716579B2 (en) Divalent vaccine compositions and the use thereof for treating tumours
BR112016002174B1 (pt) Composição de vacina